Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.930
-0.140-1.39%
Volume:45.90M
Turnover:453.22M
Market Cap:114.41B
PE:24.97
High:10.040
Open:9.955
Low:9.670
Close:10.070
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:0.55
T/O Rate:0.40%
Dividend:0.29
Dividend Rate:2.92%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.60
PE(LYR):24.97
PS:3.12

Loading ...

CSPC Pharmaceutical Group Stock Rallies 2.0% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 13

Earning Preview: CSPC PHARMA Q2 revenue expected to increase by 25.43%, institutional views are bullish

Earnings Agent
·
Aug 13

Movement Alert|CSPC PHARMA Rises 3.57% in Regular Trading, AstraZeneca siRNA Collaboration $30 Million Upfront Payment Received

Market Focus
·
Aug 13

CSPC Pharmaceutical Changes Trustee for 2018 Share Award Scheme to BOCI Trustee Hong Kong

Reuters
·
Aug 12

CSPC Pharmaceutical Group Announces Change in Trustee for 2018 Share Award Scheme

Stock News
·
Aug 12

CSPC Pharmaceutical Receives USD 30 Million Upfront Payment from AstraZeneca Under siRNA Pact

Reuters
·
Aug 12

CSPC Pharmaceutical - Receives US$30 Mln Upfront Payment from AstraZeneca on Aug 12 2026 Under Collaboration Agreement

THOMSON REUTERS
·
Aug 12

CSPC Pharma Starts Phase 1 Trial of CAR-T Drug for Relapsed, Refractory Lupus

MT Newswires Live
·
Aug 12

CSPC Pharma's SYS 6063 Trial for Lupus Clears First Site in China

Stock News
·
Aug 11

CSPC Pharmaceutical - Pharma Initiates Phase I Trial of Sys6063 for Relapsed, Refractory Sle in China

THOMSON REUTERS
·
Aug 11

Movement Alert|CSPC PHARMA Rises 3.19% in Regular Trading, Monkeypox mRNA Vaccine Receives FDA Clinical Trial Approval

Market Focus
·
Aug 11

CSPC Pharmaceutical's Mpox Vaccine Candidate Gets Trial Approval from US FDA

MT Newswires Live
·
Aug 10

CSPC Pharma Sets 20 Aug 2026 Board Meeting to Approve 1H 2026 Interim Results

Bulletin Express
·
Aug 10

CSPC Pharma (01093) Receives FDA Clearance for US Clinical Trial of Monkeypox mRNA Vaccine

Stock News
·
Aug 10

CSPC Says FDA Clears US Clinical Trial for SYS 6037 Mpox mRNA Vaccine

Reuters
·
Aug 10

CSPC Pharmaceutical - Sys6037 Mpox Mrna Vaccine Obtains FDA Clinical Trial Approval in U.S.

THOMSON REUTERS
·
Aug 10

Movement Alert|CSPC PHARMA Rises 4.43% in Regular Trading, AstraZeneca Collaboration Deepens with Milestone Payment and Joint Venture

Market Focus
·
Aug 10

CSPC Pharmaceutical Group Stock Advances 1.5% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 06

Hong Kong Stock Exchange News Highlights: Beone Medicines Sees 111% Surge in Adjusted Net Profit for First Half of the Year

Stock News
·
Aug 06

CSPC Pharma Secures US$10.00 million Milestone Payment from AstraZeneca under Small-Molecule R&D Pact

Bulletin Express
·
Aug 05